HCC

This study looks at 364 adults with advanced liver cancer that cannot be removed by surgery. It compares two treatment combinations: one using a standard procedure called TACE plus two drugs, and another using a different procedure called HAIC plus the same two drugs. The goal is…

This study tests whether giving a combination of an immunotherapy drug (sintilimab) and targeted radiation before surgery can lower the chance of liver cancer coming back. About 110 adults with resectable liver cancer will be randomly assigned to receive either the combination tr…

This study tests whether a deep learning model can identify which liver cancer patients benefit from immunotherapy (PD-1 inhibitors) after surgery to prevent the cancer from returning. About 300 adults who had their liver cancer completely removed will be followed to see if the A…

This study tests a new combination of treatments for people with liver cancer that cannot be removed by surgery and who also have high blood pressure in the liver (portal hypertension). The treatment combines a procedure called TACE with three drugs: tislelizumab (immunotherapy),…

This study tests whether adding a targeted chemoembolization procedure (TACE) to standard immunotherapy can improve outcomes for people with advanced liver cancer that cannot be removed by surgery. About 90 participants will receive both treatments to see if the combination shrin…

This early study will test a special imaging agent that targets a protein found on liver cancer cells. Six people with suspected or confirmed liver cancer will receive a low-dose radioactive tracer and then have a SPECT-CT scan. The goal is to see how the tracer moves through the…

This study looks at whether a blood test that detects tiny bits of tumor DNA (called minimal residual disease) can predict if liver cancer will come back after surgery. Researchers will follow 276 patients who had their liver cancer removed and test their blood over time. The goa…